Immatics (NASDAQ:IMTX) Stock Price Up 3.9% – Should You Buy?

Core Insights - Immatics N.V. (NASDAQ: IMTX) experienced a stock price increase of 3.9%, reaching a last traded price of $10.4630, with a significant decline in trading volume [2] - The company has a market capitalization of $1.28 billion and a P/E ratio of -10.29, indicating negative earnings performance [3] Analyst Ratings - Chardan Capital maintains a "buy" rating with a price target of $25.00 [2] - Mizuho raised its price target from $19.00 to $23.00, rating the stock as "outperform" [2] - Guggenheim increased its target price from $16.00 to $19.00, also rating it as "buy" [2] - Weiss Ratings reaffirmed a "sell (d-)" rating [2] - Zacks Research upgraded the stock from "strong sell" to "hold" [2] - The consensus rating is "Moderate Buy" with a target price of $18.80 [2] Financial Performance - For the quarter ending November 17, Immatics reported an EPS of ($0.49), exceeding the consensus estimate of ($0.50) by $0.01 [4] - The company had a negative net margin of 146.13% and a negative return on equity of 24.16% [4] - Revenue for the quarter was $6.10 million, below the expected $12.53 million [4] - Analysts project an EPS of -0.72 for the current fiscal year [4] Institutional Investment - Institutional investors and hedge funds own 64.41% of Immatics' stock [5] - Vontobel Holding Ltd. acquired a new stake worth approximately $59,000 [5] - Fox Run Management L.L.C. purchased a new position valued at $136,000 [5] - Trexquant Investment LP acquired a stake worth $783,000 [5] - Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings by 28.7%, now owning shares worth $172,000 [5] - Vanguard Personalized Indexing Management LLC bought a new stake valued at about $237,000 [5] Company Overview - Immatics N.V. is a clinical-stage biotechnology company focused on developing T cell receptor (TCR)-based immunotherapies for solid tumors [6] - The company utilizes proprietary platforms to identify tumor-specific peptide targets and develop therapies that enhance the immune response against cancer [6] - The XPRESIDENT® platform is central to Immatics' technology, aimed at discovering novel tumor antigens on cancer cells [7]